📢 Excited to share our latest review in @Frontiersin.bsky.social by Manuel Lillo, @marianozf.bsky.social and @lsoucek.bsky.social! Read here how #MYC drives #melanoma progression, plasticity and resistance: frontiersin.org/articles/10.33… @vhio.bsky.social @icreacommunity.bsky.social

Felicidades Dr. Íñigo González Larreategui! Un verdadero doctor/actor 360 ;) Te queremos!

For years, #RAS and #MYC were considered "undruggable." The success of RAS has changed the conversation. Proud to see this recent @nature.com News & Views highlighting MYC as a promising next frontier and #Peptomyc as a key player helping advance the field. www.nature.com/articles/d41...

Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments

Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.

nature.com

Exciting news for patients and for the oncology community. The Phase 3 #daraxonrasib results in mPDAC show once again that pursuing challenging targets can lead to meaningful clinical advances and that ambitious science is worth the effort. nejm.org/doi/full/10.10… #RASi #MYCi

New review just out in Frontiers in Immunology! 🎉 We dive into how #MYC reshapes the tumor–immune interface to drive #immuneescape and resistance to #immunotherapy. Open access here 👉 www.frontiersin.org/journals/imm... @vhio.bsky.social @icreacommunity.bsky.social #peptomyc

Frontiers | MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benef...

frontiersin.org

We are hiring! If you are interested in joining our Models of Cancer Therapy Laboratory lab at @vhio.bsky.social as a Research Laboratory Technician / Lab Manager, apply here: jobs.vhio.net/en/jobs/7018...

2026-002-01 Research Laboratory Technician / Lab Manager - VHIO

Under the leadership of Josep Tabernero, VHIO is an internationally recognized cancer center. Its multidisciplinary, collaborative model drives scientific progress and innovative cancer treatments.

jobs.vhio.net

Really happy to share our new open-access review in Frontiers in Cell and Developmental Biology 🎉 #MYC inhibition creates vulnerabilities that can be targeted with #DDR inhibitors. @vhio.bsky.social @icreacommunity.bsky.social #peptomyc @lsouceklab.bsky.social www.frontiersin.org/journals/cel...

Frontiers | The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated...

frontiersin.org

Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc @vhio.bsky.social @icreacommunity.bsky.social #peptomyc

Link to the article: www.cell.com/cell-reports...

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative breast cancer. Their findin...

cell.com

Huge thanks to Fabio Giuntini, and to the entire teams at @vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of #AECMM and the @erc.europa.eu for backing research that can make a real difference.

In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.

Our work MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer has been accepted in @cp-cellreports.bsky.social : 🚀

Our news of the week: Poster presented at the first annual @sosclc-aecc.bsky.social Symposium, showcasing the work of Ana Lopez Garza and Hugo Thabussot on #SCLC research, conducted as part of the #AECC 70% Survivorship Challenge. @vhio.bsky.social #peptomyc

Thrilled to share that our senior PhD student Íñigo Gonzalez has presented a poster on MYC inhibition and re-activation of tumor immunity in KRAS-driven NSCLC with diverse mutational profiles in @CellSymposia Cancer-Immunity Cycle. #ImmunoOncology #CancerTreatment #CSCancerImmunity2025

Honored to present our MYC inhibitor research at the Cancer–Immunity Cycle @CellSymposia and connect with leaders in immuno-oncology. Presented by Silvia Casacuberta 👏 #CancerResearch #ImmunoOncology #CancerTreatment #CSCancerImmunity2025

Being normal is overrated. Happy Halloween from the LSoucek lab!

Proud to see our Íñigo González Larreategui presenting a flash talk and poster at #aseicacongress in Bilbao on the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes. 👏 @aseica.bsky.social

Intense week for @LSoucekLab! We are happy to see our @dcapi14 presenting a poster on Targeting oncogene cooperation: MYC inhibition enhances response and overcomes resistance to KRAS inhibitors. #TargetingRAS2025 @TargetingRAS Targeting RAS symposium, Salamanca, 2025 👏💪

We are delighted to share that the review “MYC in cancer: from undruggable target to clinical trials” by Jonathan Whitfield and @lsoucek.bsky.social is finally out in Nature Review Drug Discovery. What an amazing journey this has been and still promises to be! rdcu.be/eawOK

MYC in cancer: from undruggable target to clinical trials

Nature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...

rdcu.be

@lsoucek.bsky.social is presenting today a seminar at UB regarding the challenge associated to the development of a MYC inhibitor. Info below.